Smith On Stocks
Contributor since: 2011
Northwest Bio: FDA Panel Recommendation On Amgen's Cancer Vaccine Is Significant For DCVax-L And DCVax Direct
Northwest Biotherapeutics: Encouraging Survival Results In 51 Glioblastoma Multiforme Patients
Northwest Has A Differentiated Technology Platform In The Emerging Immuno-Oncology Landscape
Northwest Biotherapeutics: An Analysis Of What We Know About DCVax Direct
Northwest Biotherapeutics: Capital Raise Of $35 Million Could Be A Positive Catalyst For The Stock
Celldex Therapeutics: Interim Results For Phase 2 ReACT Trial Are Very Encouraging
Cytokinetics Is Planning New Phase 3 Trial For Tirasemtiv In ALS Using New Endpoint
Discovery Laboratories: Collaboration With Battelle Is Validation Of Aerosurf's Potential By A Sophisticated Third Party
Northwest Biotherapeutics: U.K. May Grant Early Patient Access For DCVax-L Prior To Formal Approval
ImmunoCellular: Thoughts On Management's Plan To Move ICT-107 Into Phase 3
Antares: An Analysis Of FDA Briefing Documents For September 17th Advisory Committee Meeting On Testosterone Replacement Products
Cytokinetics: Will The FDA Agree To A New Phase 3 Trial For Tirasemtiv?
Northwest Bio: The Data Monitoring Committee Addresses The Status Of The DCVax-L Trial
Northwest Biotherapeutics: Responding To Richard Pearson's Article Alleging A Promotion Scheme
Discovery Laboratories: Surfaxin Launch Has Been Slow, But Clinical Trials Of Aerosurf Are Beginning At Last
ImmunoCellular Plans To Move ICT-107 Forward Into Phase III Trials Based On New Sub-Group Analysis Presented At ASCO
Northwest Biotherapeutics: Management Discusses Interim Data On Phase I/II Trial Of DCVax-Direct
Northwest Biotherapeutics Reports On Sarcoma Patient Treated With DCVAx-Direct
Ed Quilty, CEO Of Derma Sciences, Outlines His Strategy To Build A Premier Wound Healing Company
Refuting The Latest Negative Blog On Northwest Biotherapeutics
Chimerix: A Company Focused On Infectious Viral Diseases With Investment Characteristics Similar To Trius
Analysis: Northwest Biotherapeutics DCVax-L Germany Approval Under Hospital Exemption Early Access Program
Agenus: Acquisition Of 4-Antibody Is A Transformational Move
Cytokinetics: Institutional Investors Give BENEFIT-ALS Potential Results A Vote Of Confidence
Derma Sciences: A Not Well Followed Growth Company With Solutions For Diabetic Foot Ulcers
Cadence: What To Do With The Proceeds And A Post Mortem On A Successful Investment
Cadence: Patent Settlement With Sandoz Increases Confidence That Ofirmev Will Have Exclusivity Through December 6, 2020
Neuralstem: Sizing Up Potential Key Events Of 2014
Agenus: Key Opinion Leader Support Builds For Prophage
Highlights Of Recent PSivida Presentation
Thoughts On The Price Surge Of Cytokinetics
Senesco Offers A New Approach To Cancer Treatment And Dr. Phillip Frost Is Now With The Company